X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Zynlonta (loncastuximab tesirine) is a CD19-directed antibody drug conjugate, which is being evaluated in combination with glofitamab & obinutuzumab for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Lead Product(s): Loncastuximab Tesirine,Glofitamab,Obinutuzumab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is approved by FDA and EU for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Overland Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
ADC Therapeutics' CD19-specific Antibody Drug Conjugate (ADC), Zynlonta (loncastuximab tesirine-lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is being developed in combination with rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC), Loncastuximab Tesirine-lpyl. Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Zynlonta (loncastuximab tesirine) is a CD19-directed antibody drug conjugate. Once bound to a CD19-expressing cell, Zynlonta is internalised by the cell, where enzymes release a pyrrolobenzodiazepine payload.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The opinion is based on data from LOTIS-2, a large (n=145) Phase 2 multinational, single-arm clinical trial of ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory DLBCL following two or more prior lines of systemic therapy.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
The financing will enable and support to continue maximizing the potential of ZYNLONTA and advancing the pipeline of novel antibody drug conjugates for hematologic malignancies and solid tumors.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Owl Rock
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 15, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl), is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Overland Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Zynlonta (loncastuximab tesirine-lpyl), is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
ACD Therapeutics is delighted to partner with HealthCare Royalty, a leading healthcare investment firm, to continue the development and commercialization of ZYNLONTA in combination with other drugs, in earlier lines of therapy.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: HealthCare Royalty
Deal Size: $325.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 26, 2021
Details:
The first $65 million was received upon completion of the Company’s initial public offering in May 2020, and the second tranche of $50 million has now been received following the recent U.S. FDA accelerated approval of ZYNLONTA.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Partners
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 17, 2021
Details:
Single-agent ZYNLONTA demonstrated clinically important outcomes in the pivotal LOTIS-2 study across several disease subtypes. ZYNLONTA, a CD19-targeted antibody drug conjugate (ADC), has been granted accelerated approval by the FDA based on overall response rate.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
ADC Therapeutics has initiated an expanded access program (EAP) for loncastuximab tesirine (Lonca, formerly ADCT-402) for patients in the U.S. with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine,Ibrutinib
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT BioPharma. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics, 49%.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Overland Pharmaceuticals
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 14, 2020
Details:
The BLA submission is based on data from LOTIS 2, the pivotal Phase 2 multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Lonca in patients with relapsed or refractory DLBCL following two or more lines of prior therapy.
Lead Product(s): Loncastuximab Tesirine,Ibrutinib
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Eight abstracts have been selected for presentation at the 62nd ASH Annual Meeting. Presentations will feature data on three of the Company’s pyrrolobenzodiazepine (PBD)-based ADCs – loncastuximab tesirine (Lonca), camidanlumab tesirine (Cami) and ADCT-602.
Lead Product(s): Loncastuximab Tesirine,Ibrutinib
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
The BLA submission is based on data from LOTIS 2, the pivotal Phase 2 multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Lonca in patients with relapsed or refractory DLBCL following ≥2 lines of prior systemic therapy.
Lead Product(s): Loncastuximab Tesirine,Ibrutinib
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Based on the encouraging interim data Lonca and ibrutinib demonstrated in Phase 1, the trial was amended to a Phase 1/2 protocol intended to support the submission of a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Lead Product(s): Loncastuximab Tesirine,Ibrutinib
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
Interim results of the Phase 1/2 trial of Lonca in combination with ibrutinib show an encouraging overall response rate of 75.0% and complete response rate of 58.3% at the recommended Phase 2 Lonca dose.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Updated interim data from the pivotal Phase 2 trial of Lonca in patients with relapsed or refactory diffuse large B-cell lymphoma as well as interim results of a Phase 1/2 trial highlighting the potential to advance Lonca into earlier lines of therapy in combination therapies.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
ADC Therapeutics company is developing antibody drug conjugates, cancer drugs that link a tumor-targeting antibody to a cancer-killing chemical compound.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
